Our personal recommendations during the coronavirus disease 2019 (COVID-19) pandemic on the management of patients with locally advanced, metastatic and oligometastatic renal cell carcinoma (RCC). VEGF TKI, vascular endothelial growth factor tyrosine kinase inhibitor. aPatients with a history of an active autoimmune condition, with a previous life-threatening autoimmune condition, receiving chronic immunosuppressive medication or with other high-risk features of developing immune-related adverse events (irAEs). bIn patients with an intermediate risk of developing irAEs, such as patients with psoriasis, coeliac disease or type 1 diabetes mellitus, consider upfront axitinib monotherapy followed by addition of pembrolizumab when COVID-19 risk subsides. cFavourable features in the oligometastatic setting include >12-month disease-free interval after nephrectomy, low-grade tumour, good performance status and lung-only metastasis.